| abstract |
REFERS TO DERIVATIVES OF BIARIL OXAZOLES OF FORMULA I, WHERE n IS 2-4; V IS O, S; W IS O, S, SO2; R1 IS H, C1-C4 ALKYL, PHENYL, TRIFLUOROMETHYL; R2 IS H, C1-C6 ALKYL, ARYL-C1-C6 ALKYL, AMONG OTHERS; R3 IS H, C1-C6 ALKYL, ARYL-C1-C6 ALKYL, AMONG OTHERS; R4 IS H, C1-C4 ALKYL, ARYL, BENZYL; R5 IS H, ARYL, HETEROARYL; R6 IS H, C1-C4 ALKYL, AMINOALKYL. PREFERRED COMPOUNDS ARE 2- {4- [2- (2-BIPHENYL-4-IL-5-METHYLOXAZOLE-4-IL) ETOXY] NAPHTHALEN-1-ILOXI} -2-METHYLPROPIONIC ACID, 2- {4- [2 - (2-BIPHENYL-4-IL-5-METHYLOXAZOLE-4-IL) ETOXY] -5,6,7,8-TETRAHIDRONAFTALEN-1-ILOXI} -2-METHYL-PROPIONIC, ACID 2- {3- [2 - (2-ARYLPHENYLOXAZOLE-5-SUBSTITUTED-4-IL) ETOXY] 2-PHENOXY} ETHANOIC, ACID 2- (4- {2- [2- (4-THIOFEN-2-IL-PHENYL) -5-METHYLOXAZOLE- 4-IL] ETHOXY} PHENOXY) -2-METHYLPROPIONIC, AMONG OTHERS. IT ALSO REFERS TO A PROCEDURE FOR THE PREPARATION OF SUBSTITUTE 2- (BROMOPHENYL) -4- (2-HYDROXYETHYL) OXAZOL-5. COMPOUND I IS AN ACTIVATED PEROXISOME PROLIFERATOR RECEPTOR MODULATOR รพ, REDUCES TRIGLYCERIDES AND MAY BE USEFUL FOR THE TREATMENT OF DIABETES MELLITUS, SYNDROME X |